HSK39004
/ Haisco
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
August 26, 2025
Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)
(clinicaltrials.gov)
- P2 | N=50 | Active, not recruiting | Sponsor: Haisco Pharmaceutical Group Co., Ltd.
New P2 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases
August 08, 2025
Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)
(clinicaltrials.gov)
- P2 | N=180 | Not yet recruiting | Sponsor: Haisco Pharmaceutical Group Co., Ltd.
New P2 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases
May 14, 2025
Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HSK39004 Dry Powder Inhalation
(clinicaltrials.gov)
- P1 | N=26 | Completed | Sponsor: Haisco Pharmaceutical Group Co., Ltd.
New P1 trial
1 to 3
Of
3
Go to page
1